Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) GlobeNewswire - Thu Dec 18, 7:00AM CST

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings,...

OVID : 1.7600 (-1.12%)
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer GlobeNewswire - Tue Dec 2, 6:00AM CST

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today...

OVID : 1.7600 (-1.12%)
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results GlobeNewswire - Wed Nov 12, 6:00AM CST

Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of Directors Next-generation GABA-aminotransferase (GABA-AT)...

OVID : 1.7600 (-1.12%)
B. Riley Securities Sticks to Their Buy Rating for Ovid Therapeutics (OVID) Tipranks - Fri Oct 10, 3:28PM CDT

B. Riley Securities analyst Madison Elsaadi maintained a Buy rating on Ovid Therapeutics today and set a price target of $5.00. The company’s shares closed today at $1.74.Elevate Your Investing Strategy:...

OVID : 1.7600 (-1.12%)
Oppenheimer upgrades Ovid Therapeutics (OVID) to a Buy Tipranks - Fri Oct 10, 2:56AM CDT

In a report released today, Jay Olson from Oppenheimer upgraded Ovid Therapeutics to a Buy, with a price target of $7.00. The company’s shares closed yesterday at $1.58.Elevate Your Investing Strategy:...

OVID : 1.7600 (-1.12%)
Wedbush Sticks to Its Buy Rating for Ovid Therapeutics (OVID) Tipranks - Sat Oct 4, 4:30PM CDT

Wedbush analyst Laura Chico maintained a Buy rating on Ovid Therapeutics today and set a price target of $5.00. The company’s shares closed today at $1.84.Elevate Your Investing Strategy: Take advantage...

OVID : 1.7600 (-1.12%)
Ovid Therapeutics Secures $175.1M in Private Placement Tipranks - Sat Oct 4, 4:30PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ovid Therapeutics...

OVID : 1.7600 (-1.12%)
William Blair Sticks to Its Buy Rating for Ovid Therapeutics (OVID) Tipranks - Sat Oct 4, 11:58AM CDT

In a report released today, Myles Minter from William Blair maintained a Buy rating on Ovid Therapeutics. The company’s shares opened today at $2.00.Elevate Your Investing Strategy: Take advantage of...

OVID : 1.7600 (-1.12%)
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds GlobeNewswire - Fri Oct 3, 6:05AM CDT

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet...

OVID : 1.7600 (-1.12%)
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile GlobeNewswire - Fri Oct 3, 6:00AM CDT

An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metrics OV329 matched or exceeded inhibition demonstrated by therapeutic...

OVID : 1.7600 (-1.12%)

Barchart Exclusives

AI Bubble Fears Scaring You Off? Buy This Magnificent 7 Stock for Stability. Barchart - 1 hour ago
Apple has long been seen as an AI laggard. However, the stock could fit into portfolios of investors worried about an AI bubble. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot